NovoCure Limited (NASDAQ:NVCR) is considered one of the best medical device stocks to buy by analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating with a price target of $33.00. The company reported solid fiscal Q2 2025 results, exceeding revenue expectations with $158.8 million due to a rise in active patient numbers. Despite initial mixed metrics, Optune Lua in non-small cell lung cancer showed notable growth in prescriptions and active patients, indicating future potential. NovoCure Limited develops, manufactures, and commercializes Optune to treat solid tumors using electric fields tuned to specific frequencies. While NVCR offers potential as an investment, certain AI stocks may provide greater upside potential with less downside risk. Explore the best short-term AI stock for potential opportunities.

Read more at Yahoo Finance: Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)